ANTIPLATELET DRUGS

The evidence in support of the safety and efficacy of aspirin in the s econdary prevention of platelet dependent vascular-occlusion is compel ling. The utility of this drug has stalled the development of potentia l competitors, such as thromboxane antagonists. The emergence of glyco protein IIb/IIIa antagonists as the most promising competitors for asp irin has focused attention on the possibility of delivering these drug s at an effective dose safely.